Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Mabpro General Information
Mabpro is developing monoclonal antibody-based immunotherapies targeting CAIX for aggressive and hypoxic tumors. Its lead candidate, CA9hu-1, is in Phase 1 clinical trials for metastatic clear cell renal cell carcinoma. The company’s approach leverages the role of CAIX as a marker of tumor hypoxia and resistance to conventional therapies. No published clinical results are available yet.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Bratislava, Bratislava region
Slovakia
Slovakia
Drug Pipeline
No pipeline data available
Key Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Mabpro Funding
No funding data available
To view Mabpro's complete valuation and funding history, request access »